Xiaoju Lv

430 total citations
18 papers, 215 citations indexed

About

Xiaoju Lv is a scholar working on Molecular Medicine, Epidemiology and Pharmacology. According to data from OpenAlex, Xiaoju Lv has authored 18 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Medicine, 8 papers in Epidemiology and 7 papers in Pharmacology. Recurrent topics in Xiaoju Lv's work include Antibiotic Resistance in Bacteria (14 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Use and Resistance (6 papers). Xiaoju Lv is often cited by papers focused on Antibiotic Resistance in Bacteria (14 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Use and Resistance (6 papers). Xiaoju Lv collaborates with scholars based in China and United States. Xiaoju Lv's co-authors include Junyan Qu, Yimei Huang, Yanbin Liu, Hui Ye, Zhiyong Zong, Huan Li, Xin Lü, Yuan-Fang Wang, Rujia Yu and Hui Ye and has published in prestigious journals such as Frontiers in Microbiology, Emerging infectious diseases and INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY.

In The Last Decade

Xiaoju Lv

16 papers receiving 210 citations

Peers

Xiaoju Lv

EPIDE

PHARM

AMB

MICRO

Ali F. Aboklaish United Kingdom

Sophie Magréault France

Dimitra Stafylaki Greece

Nicholas Rebold United States

Luigi Ronga Italy

Galina Reshedko Russia

Federica Sacco Italy

Jonathan C. Cho United States

Ahmad Nusair United States

Ana Fleites Spain

Ali F. Aboklaish United Kingdom

Xiaoju Lv

170 ×1.6

77 ×0.8

EPIDE

75 ×1.2

PHARM

41 ×0.8

AMB

52 ×1.5

MICRO

Citations per year, relative to Xiaoju Lv Xiaoju Lv (= 1×) peers Ali F. Aboklaish

Countries citing papers authored by Xiaoju Lv

Since Specialization

Citations

This map shows the geographic impact of Xiaoju Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoju Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoju Lv more than expected).

Fields of papers citing papers by Xiaoju Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoju Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoju Lv. The network helps show where Xiaoju Lv may publish in the future.

Co-authorship network of co-authors of Xiaoju Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoju Lv. A scholar is included among the top collaborators of Xiaoju Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoju Lv. Xiaoju Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Tang, Guangmin, et al.. (2025). Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis. Microorganisms. 13(1). 55–55.

Ye, Fan, et al.. (2025). The synergistic antibacterial effects of α-mangostin and colistin on colistin-resistant Gram-negative bacteria. Journal of Global Antimicrobial Resistance. 45. 310–321.

Feng, Yu, et al.. (2024). Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance. European Journal of Clinical Microbiology & Infectious Diseases. 43(10). 2029–2035. 1 indexed citations

Feng, Yu, et al.. (2024). Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime–Avibactam in an ST11 Klebsiella pneumoniae Strain. Microorganisms. 12(6). 1193–1193. 1 indexed citations

Qu, Junyan, et al.. (2023). Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents. 62(2). 106872–106872. 10 indexed citations

Yang, Yongqiang, et al.. (2023). The impact of three carbapenems at a single-day dose on intestinal colonization resistance against carbapenem-resistant Klebsiella pneumoniae. mSphere. 8(6). e0047923–e0047923. 5 indexed citations

Lü, Xin, et al.. (2022). Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections. Frontiers in Medicine. 9. 1067548–1067548. 16 indexed citations

Lü, Xin, et al.. (2022). Treatment of Central Nervous System Infection Caused by Multidrug-Resistant Klebsiella pneumoniae with Colistin Sulfate Intravenously and Intrathecally: A Case Report. Pharmaceuticals. 15(12). 1482–1482. 3 indexed citations

Qu, Junyan, et al.. (2021). Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection. International Journal of Antimicrobial Agents. 57(3). 106284–106284. 12 indexed citations

10.

Zhong, Hongyan, Zhixing Chen, Fang He, et al.. (2021). Emergomyces orientalis Emergomycosis Diagnosed by Metagenomic Next-Generation Sequencing. Emerging infectious diseases. 27(10). 2740–2742. 8 indexed citations

11.

Wang, Yuan-Fang, et al.. (2020). Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam. Journal of Global Antimicrobial Resistance. 23. 404–407. 16 indexed citations

12.

Qu, Junyan, et al.. (2020). Synergistic Antibacterial Activity of Combined Antimicrobials and the Clinical Outcome of Patients With Carbapenemase-Producing Acinetobacter baumannii Infection. Frontiers in Microbiology. 11. 541423–541423. 10 indexed citations

13.

Qu, Junyan, Yimei Huang, & Xiaoju Lv. (2019). Crisis of Antimicrobial Resistance in China: Now and the Future. Frontiers in Microbiology. 10. 2240–2240. 61 indexed citations

14.

Hu, Yiyi, et al.. (2018). Acinetobacter sichuanensis sp. nov., recovered from hospital sewage in China. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY. 68(12). 3897–3901. 4 indexed citations

15.

Lv, Xiaoju, et al.. (2017). Research progress on polymyxin resistance mediated by mcr-1. 42(12). 1061–1068. 3 indexed citations

16.

Wang, Xiaohui, Xiaoke Zhang, Zhiyong Zong, et al.. (2013). Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.. PubMed. 138(6). 995–1002. 13 indexed citations

17.

Liu, Yanbin, et al.. (2011). PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review & meta-analysis.. PubMed. 134. 270–80. 51 indexed citations

18.

Xia, Peiyuan, et al.. (2001). Accumulation of ofloxacin and tosufloxacin in fluoroquinolone-resistant E coli.. PubMed. 22(3). 210–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact